article
Potential blockbuster drugs to watch in 2025
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
List view / Grid view
Almirall
news
EC approves lebrikizumab for atopic dermatitis
Monoclonal antibody, lebrikizumab, is approved in Europe for treatment of adults and adolescents with moderate-to-severe atopic dermatitis.
news
Could Eli Lilly deliver first-line atopic dermatitis treatment?
Strong evidence of long-term efficacy of the IL-13 inhibitor lebrikizumab for atopic dermatitis has been demonstrated in Eli Lilly’s two-year extension trial.
news
Almirall exercises option to acquire 100% of ThermiGen
4 January 2016 | By Victoria White
ThermiGen is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications...
news
Almirall’s full-year 2014 results are in line with guidance
23 February 2015 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, has posted its full-year 2014 results...
news
Almirall’s year to date results 2014: In line with guidance
10 November 2014 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, announced year to date 2014 results...
news
Almirall completes deal with Astrazeneca in respiratory disease
3 November 2014 | By Almirall
Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied...
